Mutations in Specific Codons of the KRAS Oncogene are Associated with Variable Resistance to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma

Duldulao, Marjun; Lee, Wendy; Nelson, Rebecca; Li, Wenyan; Chen, Zhenbin; Kim, Joseph; Garcia-Aguilar, Julio
July 2013
Annals of Surgical Oncology: An Oncology Journal for Surgeons;Jul2013, Vol. 20 Issue 7, p2166
Academic Journal
No abstract available.


Related Articles

  • Impact of Specific KRAS Mutation in Exon 2 on Clinical Outcome of Chemotherapy- and Radiotherapy-Treated Colorectal Adenocarcinoma Patients. Roszkowski, Krzysztof; Zurawski, Bogdan; Jozwicki, Wojciech; Basta, Pawel; Lewandowska, Marzena // Molecular Diagnosis & Therapy;Oct2014, Vol. 18 Issue 5, p559 

    Background and Objectives: Knowledge obtained via high-throughput technologies, used for tumor genome sequencing or identifying gene expression and methylation signatures, is clinically applicable thanks to molecular characterization in the context of tumor development and progression. This...

  • Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. Ihle, Nathan T.; Byers, Lauren A.; Kim, Edward S.; Saintigny, Pierre; Lee, J. Jack; Blumenschein, George R.; Tsao, Anne; Liu, Suyu; Larsen, Jill E.; Wang, Jing; Diao, Lixia; Coombes, Kevin R.; Chen, Lu; Zhang, Shuxing; Abdelmelek, Mena F.; Tang, Ximing; Papadimitrakopoulou, Vassiliki; Minna, John D.; Lippman, Scott M.; Hong, Waun K. // JNCI: Journal of the National Cancer Institute;Feb2012, Vol. 104 Issue 3, p228 

    Background Mutations in the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) play a critical role in cancer cell growth and resistance to therapy. Most mutations occur at codons 12 and 13. In colorectal cancer, the presence of any mutant KRas amino acid substitution is a negative...

  • Signature of microsatellite instability, KRAS and BRAF gene mutations in German patients with locally advanced rectal adenocarcinoma before and after neoadjuvant 5-FU radiochemotherapy. Demes, Melanie; Scheil-Bertram, Stefanie; Bartsch, Holger; Fisseler-Eckhoff, Annette // Journal of Gastrointestinal Oncology;Jun2013, Vol. 4 Issue 2, p182 

    Background: Multiple activating mutations of the signal- and repair pathway, such as BRAF-, KRASmutations and microsatellite instabilities are involved in colorectal cancer pathogenesis. Molecular characterization of specifically locally advanced rectal cancers is scarce. Therefore the...

  • Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas. Silan, Fatma; Gultekin, Yener; Atik, Sinem; Kilinc, Davran; Alan, Cabir; Yildiz, Fazilet; Uludag, Ahmet; Ozdemir, Ozturk // Molecular Biology Reports;Feb2012, Vol. 39 Issue 2, p1595 

    Prostate cancer is a common malignancy that develops by structural mutation(s) and/or other genetic alterations in specific genes.The G to T transversions in codon 12 and C to T transitions in codon 13 of KRAS proto-oncogene are predominant point mutations that occur in about 20% of different...

  • Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Imamura, Yu; Lochhead, Paul; Yamauchi, Mai; Kuchiba, Aya; Zhi Rong Qian; Xiaoyun Liao; Nishihara, Reiko; Seungyoun Jung; Wu, Kana; Nosho, Katsuhiko; Wang, Yaoyu E.; Shouyong Peng; Bass, Adam J.; Haigis, Kevin M.; Meyerhardt, Jeffrey A.; Chan, Andrew T.; Fuchs, Charles S.; Ogino, Shuji // Molecular Cancer;2014, Vol. 13 Issue 1, p1 

    Background KRAS mutations in codons 12 and 13 are established predictive biomarkers for anti-EGFR therapy in colorectal cancer. Previous studies suggest that KRAS codon 61 and 146 mutations may also predict resistance to anti-EGFR therapy in colorectal cancer. However, clinicopathological,...

  • Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma. Vagaja, N. N.; Parry, J.; McCallum, D.; Thomas, M. A.; Bentel, J. M. // Journal of Clinical Pathology;Aug2015, Vol. 68 Issue 8, p657 

    Mutations of the human Kirsten rat sarcoma viral oncogene homologue (KRAS) and the highly homologous human neuroblastoma RAS viral oncogene homologue (NRAS) are associated with resistance to antiepidermal growth factor receptor therapies in patients with colorectal cancer. In this report, we...

  • Analysis of the role of RAS Family Mutations in Metastatic Colorectal Cancer (mCRC): Current Treatment Practice. Saridaki, Zenia; Souglakos, John; Georgoulias, Vassilis; Douillard, Jean-Yves // Forum of Clinical Oncology;2014, Vol. 5 Issue 2, p12 

    A major challenge in metastatic colorectal cancer (mCRC) is the identification of specific biomarkers that are likely to predict which patients will benefit from a specific treatment. To this date, a number of studies have shown that a tumour's mutational profile influences treatment outcome in...

  • Prevalence of K-RAS Codons 12 and 13 Mutations in Locally Advanced Head and Neck Squamous Cell Carcinoma and Impact on Clinical Outcomes. Bissada, Eric; Abboud, Olivier; Chacra, Zahi Abou; Guertin, Louis; Weng, Xiaoduan; Nguyen-Tan, Phuc Félix; Tabet, Jean-Claude; Thibaudeau, Ève; Lambert, Louise; Audet, Marie-Lise; Fortin, Bernard; Soulières, Denis // International Journal of Otolaryngology;2013, p1 

    Background. RAS genemutations have an impact on treatment response and overall prognosis for certain types of cancer. Objectives. To determine the prevalence and impact of K-RAS codons 12 and 13 mutations in patients with locally advanced HNSCC treated with primary or adjuvant chemo-radiation....

  • Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. Di Nicolantonio, Federica; Arena, Sabrina; Tabernero, Josep; Grosso, Stefano; Molinari, Francesca; Macarulla, Teresa; Russo, Mariangela; Cancelliere, Carlotta; Zecchin, Davide; Mazzucchelli, Luca; Sasazuki, Takehiko; Shirasawa, Senji; Geuna, Massimo; Frattini, Milo; Baselga, José; Gallicchio, Margherita; Biffo, Stefano; Bardelli, Alberto; Baselga, José // Journal of Clinical Investigation;Aug2010, Vol. 120 Issue 8, p2858 

    Personalized cancer medicine is based on the concept that targeted therapies are effective on subsets of patients whose tumors carry specific molecular alterations. Several mammalian target of rapamycin (mTOR) inhibitors are in preclinical or clinical trials for cancers, but the molecular basis...

  • KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. Messner, Isabelle; Cadeddu, Giuseppe; Huckenbeck, Wolfgang; Knowles, Helen; Gabbert, Helmut; Baldus, Stephan; Schaefer, Karl-Ludwig // Journal of Cancer Research & Clinical Oncology;Feb2013, Vol. 139 Issue 2, p201 

    Purpose: Targeted therapies using the anti-EGFR antibodies panitumumab (Pmab) or cetuximab (Cmab) are currently restricted to patients with metastatic colorectal adenocarcinoma whose tumours do not show a mutation in KRAS. However, recent retrospective studies indicated that patients with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics